🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 67 of 116

  1. Puregon 300 IU/0.36 mL solution for injection, Cetrotide 0.25 mg powder and solvent for solution for injection, NOLVADEX 10 mg, comprimé pelliculé, Ovitrelle 250 micrograms solution for injection in pre-filled pen

    CERO THERAPEUTICS HOLDINGS, INC.

    Breast cancer

    phase 2 small molecule active

    1 trial

  2. Pyrotinib

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  3. Pyrotinib, trastuzumab, paclitaxel-albumin

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  4. QINLOCK 50 mg tablets

    Lacuna Pharma Pty Ltd

    Advanced gastrointestinal stromal tumor (GIST)

    phase 2 small molecule active

    1 trial

  5. QL1706

    The First People's Hospital of Lianyungang

    Local Advanced Esophageal Cancer

    phase 2 small molecule active

    1 trial

  6. QL1706

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Platinum-resistant Recurrent Ovarian Cancer

    phase 2 small molecule active

    1 trial

  7. QL1706 (Iparomlimab/Tuvonralimab)

    The First People's Hospital of Lianyungang

    Gastric Cancer Stage III

    phase 2 small molecule active

    1 trial

  8. QL1706 (bispecific antibody targeting PD-1 and CLTA-4)

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 2 small molecule active

    1 trial

  9. Quemliclustat

    Arcus Biosciences

    Oligometastatic Prostate Cancer

    phase 2 small molecule active

    1 trial

  10. Quizartinib

    Daiichi Sankyo

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  11. RC48-ADC

    Chinese University of Hong Kong

    Muscle Invasive Bladder Carcinoma

    phase 2 small molecule active

    1 trial

  12. RD14-01

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solid Tumor

    phase 2 mab active

    1 trial

  13. REGN10597

    Regeneron UK Limited

    Melanoma

    phase 2 small molecule active

    1 trial

  14. REGN15505

    Regeneron UK Limited

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  15. REGN2810

    Regeneron UK Limited

    Prostate Cancer Metastatic

    phase 2 small molecule active

    1 trial

  16. REGN4336

    Regeneron UK Limited

    Metastatic Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  17. REGN5093

    Lacuna Pharma Pty Ltd

    MET-altered non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  18. REGN5668

    Regeneron UK Limited

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  19. REGN5678

    Regeneron UK Limited

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  20. REGN7075

    Regeneron UK Limited

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  21. RELUGOLIX

    Fondazione Telethon ETS

    Intermediate risk prostate cancer

    phase 2 small molecule active

    1 trial

  22. REOLYSIN

    ONCOLYTICS BIOTECH INC

    Metastatic Pancreatic Adenocarcinoma

    phase 2 mab completed

    1 trial

  23. REOLYSIN

    ONCOLYTICS BIOTECH INC

    Metastatic or Recurrent Squamous Cell Carcinoma of the Lung

    phase 2 mab completed

    1 trial

  24. REOLYSIN

    ONCOLYTICS BIOTECH INC

    Metastatic Melanoma

    phase 2 mab completed

    1 trial

  25. REOLYSIN®

    ONCOLYTICS BIOTECH INC

    Carcinoma, Non-small Cell Lung

    phase 2 mab completed

    1 trial

  26. REOLYSIN®

    ONCOLYTICS BIOTECH INC

    Osteosarcoma

    phase 2 mab completed

    1 trial

  27. RITUXIMAB , DOXORUBICIN , VINCRISTINE , IBRUTINIB , RITUXIMAB, PREDNISONE , CYCLOPHOSPHAMIDE

    Fondazione Telethon ETS

    Diffuse Large B-cell Lymphoma ABC

    phase 2 small molecule active

    1 trial

  28. RITUXIMAB, CYCLOPHOSPHAMIDE , AZD0486, PREDNISOLONE , VINCRISTINE , Calquence 100 mg film-coated tablets, RITUXIMAB , AZD0486, DOXORUBICIN , Calquence 100 mg film-coated tablets, PREDNISONE , AZD0486, AZD0486

    AstraZeneca AB

    Mantle Cell Lymphoma, Large B-Cell Lymphoma, Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma

    phase 2 small molecule active

    1 trial

  29. RITUXIMAB, Golcadomide

    Fondazione Telethon ETS

    Diffuse Large B-cells non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  30. RMC-4630

    Revolution Medicines

    Solid Tumor

    phase 2 small molecule completed

    1 trial

  31. RMC-4630

    Revolution Medicines

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  32. RMC-6236

    Revolution Medicines

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  33. RMC-6236

    Revolution Medicines

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  34. RMC-9805

    Revolution Medicines

    Lung Cancer

    phase 2 small molecule active

    1 trial

  35. RO7197597

    Hoffmann-La Roche

    Grade 1 Endometrial Cancer

    phase 2 small molecule active

    1 trial

  36. RO7247669

    Hoffmann-La Roche

    Unresectable or Metastatic Melanoma

    phase 2 small molecule active

    1 trial

  37. RO7247669

    Hoffmann-La Roche

    Melanoma

    phase 2 small molecule completed

    1 trial

  38. RO7790118, RO7791094, RO7790118, Tiragolumab, Avastin 25 mg/ml concentrate for solution for infusion., RO7247669, Tecentriq 1 200 mg concentrate for solution for infusion, RO7790118, TPST-1120, ADG126, RoActemra 20 mg/mL concentrate for solution for infusion

    Hoffmann-La Roche

    Advanced liver cancers

    phase 2 small molecule active

    1 trial

  39. RO7881583, EMPAGLIFLOZIN, Fulvestrant EVER Pharma 250 mg Injektionslösung in einer Fertigspritze, SACITUZUMAB GOVITECAN , Verzenios 100 mg film-coated tablets, EMPAGLIFLOZIN, PALBOCICLIB, INAVOLISIB, Tecentriq 1 200 mg concentrate for solution for infusion, LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, PALBOCICLIB, PALBOCICLIB, RoActemra 20 mg/mL concentrate for solution for infusion, Kisqali 200 mg film-coated tablets, Verzenios 50 mg film-coated tablets, Tecentriq, Abraxane 5 mg/ml powder for di

    Hoffmann-La Roche

    Metastatic breast cancer, including triple negative breast cancer (TNBC), hormone receptor positive breast cancer (HR+ BC), and HER2 positive and HER2 low breast cancer (HER2+/HER2-low BC)

    phase 2 small molecule active

    1 trial

  40. RUBIDIUM CHLORIDE

    Pari Pharma GmbH

    Kidney carcinoma

    phase 2 small molecule active

    1 trial

  41. RX-3117

    Processa Pharmaceuticals

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  42. RX-3117

    Processa Pharmaceuticals

    Solid Tumor

    phase 2 small molecule completed

    1 trial

  43. Radiation: Radiation Therapy；Biological: Personalized tumor peptide vaccine

    Hospital Authority, Hong Kong

    Advanced Tumors

    phase 2 other active

    1 trial

  44. Radio-guided sentinel node biopsy

    Hospital Authority, Hong Kong

    Cancer of the Breast

    phase 2 other terminated

    1 trial

  45. Radiochemoimmunotherapy

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 other active

    1 trial

  46. Radiotherapy

    The First People's Hospital of Lianyungang

    Cholangiocarcinoma

    phase 2 other terminated

    1 trial

  47. Radiotherapy Combined with Anlotinib and a Microtubule Inhibitor

    The First People's Hospital of Lianyungang

    HER2-Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  48. Radium-223 dichloride (Xofigo, BAY88-8223)

    Bayer HealthCare AG

    Breast Neoplasms

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.